Wallace Akerley, MD
Medical Oncology · Salt Lake City, UTNPI 1346330966
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,600 of the $37,780 with a category attached, or 86.3%. 9 manufacturers reported payments, led by AstraZeneca at 37.0% of the total. Reporting peaked in 2019 at $21,342 and has fallen 55.8% since, to $9,438 in 2023.
Across 49 payments — averaging $771.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$14K
- Eli Lilly$10K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- E.r. Squibb & Sons, L.L.C.$5K
- Bristol Myers Squibb$2K
- Novocure GmbH$99
- plus $67 from 3 others
Across 529 payments — averaging $23,955 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$6.6M
- Novartis$1.6M
- AbbVie$1.2M
- E.r. Squibb & Sons, L.L.C.$1.1M
- Eli Lilly$704K
- Merck$538K
- plus $1M from 10 others
What the payments were for
- Consulting fees$32,60086%
- Travel & lodging$4,20311%
- Food & beverage$9242%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $13,995 |
| Eli Lilly | 4 | $9,800 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $7,319 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,875 |
| Bristol Myers Squibb | 1 | $1,625 |
| Novocure GmbH | 1 | $99 |
| Genentech, Inc. | 1 | $40 |
| Novartis | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,780 in reported general payments places this provider in the 85th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 81 | $1,341,565 |
| LorbrenaLorlatinib | 17 | $357,994 |
| EliquisApixaban | 24 | $29,576 |
| XareltoRivaroxaban | 23 | $28,736 |
| Prochlorperazine Maleate | 43 | $677 |
| Dexamethasone | 40 | $538 |
| Levothyroxine Sodium | 41 | $337 |
| Olanzapine | 16 | $336 |
| Ondansetron Hcl | 36 | $325 |
| Ondansetron OdtOndansetron | 15 | $305 |
| Levetiracetam | 11 | $289 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $270 |
| Ibuprofen | 11 | $176 |
| Prednisone | 24 | $133 |
| Fluoxetine Hcl | 12 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $13,995 | $1,341,56581 claims |
| Johnson & JohnsonXarelto | $13 | $28,73623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 43 medical oncology providers in Utah.
Other medical oncology in Salt Lake City
- Bradley HunterSalt Lake City$263K
- Robert HavardSalt Lake City$57K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Paul ShamiSalt Lake City$28K
- Nitin ChandramouliSalt Lake City$19K
- Kenneth GrossmannSalt Lake City$15K
- Manish KohliSalt Lake City$13K
- Peter HaleSalt Lake City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.